"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
| Descriptor ID |
D000951
|
| MeSH Number(s) |
D23.050.285
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in this website by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 2 | 1 | 3 |
| 2001 | 7 | 3 | 10 |
| 2002 | 5 | 4 | 9 |
| 2003 | 2 | 4 | 6 |
| 2004 | 2 | 2 | 4 |
| 2005 | 4 | 8 | 12 |
| 2006 | 2 | 1 | 3 |
| 2007 | 4 | 5 | 9 |
| 2008 | 1 | 1 | 2 |
| 2009 | 4 | 1 | 5 |
| 2010 | 5 | 8 | 13 |
| 2011 | 6 | 2 | 8 |
| 2012 | 3 | 2 | 5 |
| 2013 | 6 | 2 | 8 |
| 2014 | 3 | 3 | 6 |
| 2015 | 2 | 5 | 7 |
| 2016 | 3 | 3 | 6 |
| 2017 | 6 | 4 | 10 |
| 2018 | 5 | 2 | 7 |
| 2019 | 5 | 4 | 9 |
| 2020 | 4 | 9 | 13 |
| 2021 | 8 | 3 | 11 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 3 | 4 |
| 2024 | 6 | 1 | 7 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles.
-
MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation. Sci Adv. 2025 Feb 14; 11(7):eads4227.
-
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 03; 31(3):529-542.
-
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clin Cancer Res. 2025 Feb 03; 31(3):573-587.
-
Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma. J Immunother Cancer. 2025 Jan 04; 13(1).
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024 Dec; 45(12):931-933.
-
Tumor-associated antigen prediction using a single-sample gene expression state inference algorithm. Cell Rep Methods. 2024 Nov 18; 4(11):100906.
-
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe. 2024 Nov 13; 32(11):2004-2018.e9.
-
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 2024 Nov 26; 43(11):114875.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.